Literature DB >> 34996837

SARS-CoV-2 NSP13 Inhibits Type I IFN Production by Degradation of TBK1 via p62-Dependent Selective Autophagy.

Chao Sui1, Tongyang Xiao2,3, Shengyuan Zhang2,3, Hongxiang Zeng2,3, Yi Zheng1, Bingyu Liu1, Gang Xu4,3, Chengjiang Gao5, Zheng Zhang4,3,6,7.   

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has seriously threatened global public health. Severe COVID-19 has been reported to be associated with an impaired IFN response. However, the mechanisms of how SARS-CoV-2 antagonizes the host IFN response are poorly understood. In this study, we report that SARS-CoV-2 helicase NSP13 inhibits type I IFN production by directly targeting TANK-binding kinase 1 (TBK1) for degradation. Interestingly, inhibition of autophagy by genetic knockout of Beclin1 or pharmacological inhibition can rescue NSP13-mediated TBK1 degradation in HEK-293T cells. Subsequent studies revealed that NSP13 recruits TBK1 to p62, and the absence of p62 can also inhibit TBK1 degradation in HEK-293T and HeLa cells. Finally, TBK1 and p62 degradation and p62 aggregation were observed during SARS-CoV-2 infection in HeLa-ACE2 and Calu3 cells. Overall, our study shows that NSP13 inhibits type I IFN production by recruiting TBK1 to p62 for autophagic degradation, enabling it to evade the host innate immune response, which provides new insights into the transmission and pathogenesis of SARS-CoV-2 infection.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34996837     DOI: 10.4049/jimmunol.2100684

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  6 in total

Review 1.  The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2.

Authors:  Saba R Aliyari; Natalie Quanquin; Olivier Pernet; Shilei Zhang; Lulan Wang; Genhong Cheng
Journal:  Pathogens       Date:  2022-05-03

Review 2.  Targeting Selective Autophagy as a Therapeutic Strategy for Viral Infectious Diseases.

Authors:  Yishan Liu; Tao Zhou; Jiajia Hu; Shouheng Jin; Jianfeng Wu; Xiangdong Guan; Yaoxing Wu; Jun Cui
Journal:  Front Microbiol       Date:  2022-04-28       Impact factor: 6.064

Review 3.  COVID-19 metabolism: Mechanisms and therapeutic targets.

Authors:  Tianshi Wang; Ying Cao; Haiyan Zhang; Zihao Wang; Cheuk Him Man; Yunfan Yang; Lingchao Chen; Shuangnian Xu; Xiaojing Yan; Quan Zheng; Yi-Ping Wang
Journal:  MedComm (2020)       Date:  2022-08-09

4.  SARS-CoV-2 ORF10 antagonizes STING-dependent interferon activation and autophagy.

Authors:  Lulu Han; Yi Zheng; Jian Deng; Mei-Ling Nan; Yang Xiao; Meng-Wei Zhuang; Jing Zhang; Wei Wang; Chengjiang Gao; Pei-Hui Wang
Journal:  J Med Virol       Date:  2022-07-07       Impact factor: 20.693

Review 5.  A Game of Infection - Song of Respiratory Viruses and Interferons.

Authors:  Guo Qiang Wang; Yinuo Gu; Chao Wang; Fang Wang; Alan Chen-Yu Hsu
Journal:  Front Cell Infect Microbiol       Date:  2022-06-29       Impact factor: 6.073

Review 6.  Autophagy in SARS-CoV-2 infection.

Authors:  Di Chen; Hong Zhang
Journal:  Curr Opin Physiol       Date:  2022-09-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.